MIP3α-Gp100-Trp2 DNA vaccine / Johns Hopkins Bloomberg School of Public Health - LARVOL DELTA

[VIRTUAL] The anti-tumor enhancement of a dendritic-cell targeting MIP3α-Gp100-Trp2 DNA vaccine by IFNα and 5-Aza-2’-deoxycytidine treatments correlates with intratumoral CCL19 but not CCL21 expression (AACR-II 2020) - "Efficient targeting of antigen to immature dendritic cells with a chemokine-fusion vaccine offers a potential alternative approach to classic and dendritic cell-based vaccines.Combining this approach with IFNα and 5Aza treatments significantly improved vaccine efficacy. This enhancement was correlated with CD8+ TIL recruitment and with the expression of the T-cell trafficking chemokine CCL19. Further potential therapy optimization currently undergoing investigation offers promise for this line of investigation to become a novel melanoma therapy."

Melanoma • Oncology • Solid Tumor • CCL19 • CCL21 • CD8 • CXCL10 • GZMB • Tyrosinase

IFN-α and 5-Aza-2’-deoxycytidine enhance the anti-tumor efficacy of a dendritic-cell targeting MIP3α-Gp100-Trp2 DNA vaccine by affecting T-cell and Dendritic Cell recruitment into tumor (SITC 2019) - "Efficient targeting of antigen to immature dendritic cells with a chemokine-fusion vaccine offers a potential alternative approach to classic and dendritic cell-based vaccines currently undergoing clinical investigation. Combining this approach with IFNa and Aza treatments significantly improved vaccine efficacy, with efficacy correlating with changes in TILs and tumor infiltrating DCs. Further potential therapy optimization currently undergoing investigation offers promise for this line of investigation to become a novel melanoma therapy."

Clinical